Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

Benedict Yan, Shoa Nian Choo, Patricia Mulyadi, Supriya Srivastava, Chee Wee Ong, Kol Jia Yong, Thomas Putti, Manuel Salto-Tellez, Gkeok Stzuan Diana Lim

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment.
Original languageEnglish
Pages (from-to)1097-101
Number of pages5
JournalJournal of Clinical Pathology
Volume64
Issue number12
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Sensitivity and Specificity
  • Chromosomes, Human, Pair 17
  • Ovarian Neoplasms
  • Genes, erbB-2
  • Receptor, erbB-2
  • Humans
  • Color
  • Gene Amplification
  • In Situ Hybridization
  • Adenocarcinoma, Mucinous
  • Cohort Studies
  • Immunohistochemistry
  • Female

Fingerprint

Dive into the research topics of 'Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours'. Together they form a unique fingerprint.

Cite this